IQUIX Launched at the 2007 AAO Meeting Review of Santens Portfolio

Adrienne Graves PhD, President and CEO of Santen, highlights their product portfolio from dry eye to retina and glaucoma (Alamast, Quixin, and Betimol). She is interviewed by Dr. Andrew Moshfeghi, Associate Retina Editor for OphthalmologyWeb, and Dr. David Goldman, Refractive Editor for OphthalmologyWeb. She discusses the launch of IQUIX (1.5% levofloxacin) at this year's AAO meeting in New Orleans. IQUIX is BAK-free, and has a much reduced dosing regimen compared to the other fluoroquinolones approved for corneal ulcer. Their novel rho-kinase (ROCK) inhibitor for the treatment of glaucoma is in phase I trials currently and was the subject of several presentations at the AAO showing promising results. For dry-eye, rivoglitazone (aka DE-101) is in phase II development.

Confirm contact information

Check your contact information below to see if it's correct. If so, click confirm. If this is not you, please login below.

I am looking to purchase:

Returning users login in

Last Name:
E-mail Address:

New users please register

E-mail
First Name
Last Name
Country
Html E-mail?

Address Line 1
Address Line 2
City
State/Province
Zip/Postal Code
Phone

Institution
Title
Department
Institution Type